Patient-level costs of major cardiovascular conditions: a review of the international literature
| Autor: | Ronald J. Halbert, Shravanthi R. Gandra, Gina Nicholson, Robert J. Nordyke, Akshara Richarriya |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Cost estimate hospitalization economics medicine.medical_treatment Economics Econometrics and Finance (miscellaneous) Review 030204 cardiovascular system & hematology 03 medical and health sciences Indirect costs 0302 clinical medicine health care costs medicine media_common.cataloged_instance 030212 general & internal medicine Myocardial infarction European union Activity-based costing health care economics and organizations Average cost media_common Unstable angina business.industry Health Policy Percutaneous coronary intervention medicine.disease follow-up studies cardiovascular diseases Emergency medicine business |
| Zdroj: | ClinicoEconomics and Outcomes Research: CEOR |
| ISSN: | 1178-6981 |
| DOI: | 10.2147/ceor.s89331 |
| Popis: | Objective Robust cost estimates of cardiovascular (CV) events are required for assessing health care interventions aimed at reducing the economic burden of major adverse CV events. This review synthesizes international cost estimates of CV events. Methods MEDLINE database was searched electronically for English language studies published during 2007-2012, with cost estimates for CV events of interest - unstable angina, myocardial infarction, heart failure, stroke, and CV revascularization. Included studies provided at least one estimate of patient-level direct costs in adults for any identified country. Information on study characteristics and cost estimates were collected. All costs were adjusted for inflation to 2013 values. Results Across the 114 studies included, the average cost was US $6,466 for unstable angina, $11,664 for acute myocardial infarction, $11,686 for acute heart failure, $11,635 for acute ischemic stroke, $37,611 for coronary artery bypass graft, and $13,501 for percutaneous coronary intervention. The ranges for cost estimates varied widely across countries with US cost estimate being at least twice as high as European Union costs for some conditions. Few studies were found on populations outside the US and European Union. Conclusion This review showed wide variation in the cost of CV events within and across countries, while showcasing the continuing economic burden of CV disease. The variability in costs was primarily attributable to differences in study population, costing methodologies, and reporting differences. Reliable cost estimates for assessing economic value of interventions in CV disease are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|